Estrella Immunopharma (ESLA) and Its Peers Financial Contrast

Estrella Immunopharma (NASDAQ:ESLA) is one of 300 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it weigh in compared to its peers? We will compare Estrella Immunopharma to related businesses based on the strength of its earnings, risk, profitability, institutional ownership, dividends, analyst recommendations and valuation.

Profitability

This table compares Estrella Immunopharma and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Estrella Immunopharma	N/A	-195.77%	-157.28%
Estrella Immunopharma Competitors	-2,185.76%	-161.46%	-40.62%

Analyst Ratings

This is a breakdown of recent recommendations for Estrella Immunopharma and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Estrella Immunopharma	0	0	1	0	3.00
Estrella Immunopharma Competitors	2047	5577	14306	317	2.58

Estrella Immunopharma presently has a consensus target price of $16.00, suggesting a potential upside of 1,484.16%. As a group, “Biological products, except diagnostic” companies have a potential upside of 115.13%. Given Estrella Immunopharma’s stronger consensus rating and higher probable upside, equities analysts clearly believe Estrella Immunopharma is more favorable than its peers.

Insider and Institutional Ownership

0.3% of Estrella Immunopharma shares are owned by institutional investors. Comparatively, 50.1% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 55.1% of Estrella Immunopharma shares are owned by company insiders. Comparatively, 15.2% of shares of all “Biological products, except diagnostic” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility and Risk

Estrella Immunopharma has a beta of 0.37, indicating that its share price is 63% less volatile than the S&P 500. Comparatively, Estrella Immunopharma’s peers have a beta of -4.60, indicating that their average share price is 560% less volatile than the S&P 500.

Valuation and Earnings

This table compares Estrella Immunopharma and its peers revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Estrella Immunopharma	N/A	-$7.31 million	-3.88
Estrella Immunopharma Competitors	$581.03 million	-$70.44 million	3.80

Estrella Immunopharma’s peers have higher revenue, but lower earnings than Estrella Immunopharma. Estrella Immunopharma is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Summary

Estrella Immunopharma beats its peers on 7 of the 13 factors compared.

Estrella Immunopharma Company Profile

Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.